About CorMedix (NYSEAMERICAN:CRMD)
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
SectorSpecialty & Advanced Pharmaceuticals
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-318.95%
Return on Assets-227.65%
CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
How were CorMedix's earnings last quarter?
CorMedix Inc. (NYSEAMERICAN:CRMD) announced its earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.08. The biotechnology company earned $0.04 million during the quarter, compared to the consensus estimate of $0.05 million. CorMedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%. View CorMedix's Earnings History.
When will CorMedix make its next earnings announcement?
Where is CorMedix's stock going? Where will CorMedix's stock price be in 2017?
3 brokers have issued 12-month target prices for CorMedix's shares. Their predictions range from $3.00 to $4.00. On average, they expect CorMedix's share price to reach $3.67 in the next twelve months. View Analyst Ratings for CorMedix.
Are investors shorting CorMedix?
CorMedix saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 3,699,854 shares, an increase of 12.0% from the November 15th total of 3,303,567 shares. Based on an average daily volume of 739,690 shares, the short-interest ratio is currently 5.0 days. Currently, 5.8% of the company's stock are short sold.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include UQM Technologies (UQM), GlobalSCAPE (GSB), Unique Fabricating (UFAB), McClatchy (MNI), Synthetic Biologics (SYN), Navidea Biopharmaceuticals (NAVB), Avino Silver & Gold Mines (ASM), US Geothermal (HTM), Vista Gold (VGZ), eMagin (EMAN), Rexahn Pharmaceuticals (RNN), TransAtlantic Petroleum (TAT), NovaBay Pharmaceuticals (NBY), Actinium Pharmaceuticals (ATNM), WidePoint (WYY), Pfenex (PFNX), Wireless Telecom Group (WTT) and Platinum Group Metals (PLG).
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Myron M. Kaplan, Chairman of the Board (Age 70)
- Randy Milby, Chief Executive Officer, Director (Age 61)
- Robert W. Cook, Chief Financial Officer (Age 60)
- Antony E. Pfaffle M.D., Chief Scientific Officer, Director (Age 51)
- Khoso Baluch, Director
- Gary A. Gelbfish M.D., Director (Age 54)
- Mehmood Khan M.D., Director (Age 58)
- Janet M. Dillione, Independent Director (Age 55)
- Matthew P. Duffy, Independent Director (Age 52)
How do I buy CorMedix stock?
Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CorMedix stock can currently be purchased for approximately $0.58.
How big of a company is CorMedix?
CorMedix has a market capitalization of $38.87 million.
How can I contact CorMedix?
CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for CorMedix (CRMD)MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
CorMedix (NYSEAMERICAN:CRMD) Earnings History and Estimates Chart
CorMedix (NYSEAMERICAN CRMD) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2016||Q3 2016||($0.15)||($0.23)||$0.05 million||$0.04 million||View||N/A|
|8/5/2016||Q216||($0.11)||($0.13)||$119.97 million||$16.51 million||View||N/A|
|5/10/2016||Q1||($0.09)||($0.12)||$0.11 million||$0.04 million||View||N/A|
|11/12/2015||Q3||($0.13)||($0.14)||$0.12 million||$0.04 million||View||Listen|
|8/6/2015||Q2 2015||($0.13)||($0.13)||$0.08 million||$0.12 million||View||N/A|
|3/12/2015||Q4 2014||($0.12)||($0.09)||$0.08 million||$0.09 million||View||N/A|
|11/13/2014||Q3 2014||($0.09)||($0.09)||$0.08 million||$0.05 million||View||N/A|
|8/14/2014||Q2 2014||($0.13)||($0.26)||$0.02 million||$0.04 million||View||N/A|
CorMedix (NYSEAMERICAN:CRMD) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for CorMedix (NYSEAMERICAN:CRMD)
No dividend announcements for this company have been tracked by MarketBeat.com
CorMedix (NYSEAMERICAN CRMD) Insider Trading and Institutional Ownership History
CorMedix (NYSEAMERICAN CRMD) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/12/2017||Jr. John L Armstrong||VP||Buy||20,833||$0.48||$9,999.84|| |
|12/12/2017||Khoso Baluch||CEO||Buy||104,166||$0.48||$49,999.68|| |
|12/12/2017||Robert W Cook||CFO||Buy||52,083||$0.48||$24,999.84|| |
|12/12/2017||Steven W Lefkowitz||Director||Buy||135,416||$0.48||$64,999.68|| |
|8/18/2017||Khoso Baluch||CEO||Buy||36,207||$0.42||$15,206.94|| |
|8/18/2017||Mehmood Khan||Director||Buy||400,000||$0.39||$156,000.00|| |
|8/17/2017||Myron Kaplan||Director||Buy||80,000||$0.40||$32,000.00|| |
|8/14/2017||Myron Kaplan||Director||Buy||50,000||$0.35||$17,500.00|| |
|5/30/2017||Cora M Tellez||Director||Buy||7,550||$0.42||$3,171.00|| |
|5/17/2017||Khoso Baluch||CEO||Buy||75,000||$0.48||$36,000.00|| |
|5/16/2017||Cora M Tellez||Director||Buy||50,000||$0.48||$24,000.00|| |
|5/15/2017||Janet Dillione||Director||Buy||21,231||$0.48||$10,190.88|| |
|5/15/2017||Robert W Cook||CFO||Buy||50,000||$0.50||$25,000.00|| |
|5/1/2017||Cora M Tellez||Director||Buy||4,800||$0.66||$3,168.00|| |
|3/30/2017||Cora M Tellez||Director||Buy||1,950||$1.66||$3,237.00|| |
|2/28/2017||Cora M Tellez||Director||Buy||1,540||$2.10||$3,234.00|| |
|2/7/2017||Antony Pfaffle||Insider||Sell||10,000||$2.00||$20,000.00|| |
|1/30/2017||Cora M Tellez||Director||Buy||1,780||$1.79||$3,186.20|| |
|12/30/2016||Cora M Tellez||Director||Buy||1,990||$1.58||$3,144.20|| |
|12/9/2016||Khoso Baluch||CEO||Buy||10,000||$1.77||$17,700.00|| |
|11/30/2016||Cora M Tellez||Director||Buy||1,800||$1.80||$3,240.00|| |
|10/31/2016||Cora M Tellez||Director||Buy||1,475||$2.15||$3,171.25|| |
|10/21/2016||Antony Pfaffle||Insider||Sell||20,000||$2.23||$44,600.00|| |
|9/22/2016||Janet Dillione||Director||Buy||15,000||$2.66||$39,900.00|| |
|8/25/2016||Taunia Markvicka||Director||Buy||18,600||$1.65||$30,690.00|| |
|8/19/2016||Cora M Tellez||Director||Buy||12,500||$1.73||$21,625.00|| |
|6/21/2016||Antony Pfaffle||Insider||Sell||29,657||$2.14||$63,465.98|| |
|6/20/2016||Antony Pfaffle||Insider||Sell||10,000||$2.16||$21,600.00|| |
|6/15/2016||Antony Pfaffle||Insider||Sell||4,900||$2.21||$10,829.00|| |
|6/13/2016||Antony Pfaffle||Insider||Sell||5,443||$2.27||$12,355.61|| |
|6/9/2016||Antony Pfaffle||Insider||Sell||10,000||$2.38||$23,800.00|| |
|6/8/2016||Janet Dillione||Director||Buy||3,738||$2.67||$9,980.46|| |
|6/3/2016||Matthew Duffy||Director||Sell||46,106||$2.73||$125,869.38|| |
|5/31/2016||Steven W Lefkowitz||Director||Sell||50,000||$2.88||$144,000.00|| |
|5/25/2016||Cora M Tellez||Director||Buy||8,600||$2.90||$24,940.00|| |
|5/24/2016||Antony Pfaffle||Insider||Sell||12,700||$2.73||$34,671.00|| |
|5/24/2016||Antony Pfaffle||Insider||Sell||12,700||$2.73||$34,671.00|| |
|5/23/2016||Antony Pfaffle||Insider||Sell||15,000||$2.89||$43,350.00|| |
|5/23/2016||Steven W Lefkowitz||Director||Sell||30,000||$2.93||$87,900.00|| |
|5/19/2016||Antony Pfaffle||Insider||Sell||12,300||$2.82||$34,686.00|| |
|5/16/2016||Antony Pfaffle||Insider||Sell||60,000||$2.68||$160,800.00|| |
|6/30/2015||Randy Milby||CEO||Buy||1,610||$3.88||$6,246.80|| |
|6/23/2015||Taunia Markvicka||Director||Buy||4,000||$4.81||$19,240.00|| |
|6/15/2015||Randy Milby||CEO||Buy||1,245||$5.02||$6,249.90|| |
|6/4/2015||Matthew Duffy||Director||Sell||30,000||$6.48||$194,400.00|| |
|5/29/2015||Randy Milby||CEO||Buy||1,026||$6.09||$6,248.34|| |
|2/27/2015||Randy Milby||CEO||Buy||1,211||$5.16||$6,248.76|| |
|2/13/2015||Randy Milby||CEO||Buy||1,911||$3.27||$6,248.97|| |
|1/30/2015||Randy Milby||CEO||Buy||2,016||$3.10||$6,249.60|| |
|12/15/2014||Randy Milby||CEO||Buy||4,734||$1.32||$6,248.88|| |
|11/28/2014||Randy Milby||CEO||Buy||4,464||$1.40||$6,249.60|| |
|11/14/2014||Cora M Tellez||Director||Buy||11,086||$1.52||$16,850.72|| |
|11/14/2014||Randy Milby||CEO||Buy||4,111||$1.52||$6,248.72|| |
|10/31/2014||Randy Milby||CEO||Buy||3,434||$1.82||$6,249.88|| |
|9/30/2014||Randy Milby||CEO||Buy||3,324||$1.88||$6,249.12|| |
|9/15/2014||Randy Milby||CEO||Buy||3,654||$1.71||$6,248.34|| |
|8/29/2014||Randy Milby||CEO||Buy||3,125||$2.00||$6,250.00|| |
|8/15/2014||Randy Milby||CEO||Buy||3,140||$1.99||$6,248.60|| |
|7/31/2014||Randy Milby||CEO||Buy||6,250||$2.00||$12,500.00|| |
|6/30/2014||Randy Milby||CEO||Buy||2,732||$1.83||$4,999.56|| |
|12/13/2013||Steven W Lefkowitz||Insider||Buy||18,000||$0.78||$14,040.00|| |
CorMedix (NYSEAMERICAN CRMD) News Headlines
CorMedix (NYSEAMERICAN:CRMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CorMedix (NYSEAMERICAN:CRMD) Income Statement, Balance Sheet and Cash Flow Statement
CorMedix (NYSEAMERICAN CRMD) Stock Chart for Sunday, December, 17, 2017